Effect of Pegylated-interferon (Peg-inf) Plus Ribavirin (Rbv) Therapy on Haematological Profile of Different Age Groups Infected by Hepatitis C Virus in Pakistan

Effect of Pegylated-interferon (Peg-inf) Plus Ribavirin (Rbv) Therapy on Haematological Profile of Different Age Groups Infected by Hepatitis C Virus in Pakistan | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Effect of Pegylated-interferon (Peg-inf) Plus Ribavirin (Rbv) Therapy on Haematological Profile of Different Age Groups Infected by Hepatitis C Virus in Pakistan Aziz Ur Rehman, Sajjad Ali Shah, Rehana Masood, Aisha Siddique, and 10 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5717094/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background and Aims: With an estimated 11.55% adult population carrying HCV, hepatitis is a serious public health concern in Pakistan. With almost one in every 20 Pakistanis already infected, the nation ranks second internationally in terms of hepatitis C virus (HCV) infections. HBV and HCV each have annual mortality rates of 563,000 and 366,000, respectively. Hepatocellular carcinoma (HCC) is the most common primary liver tumor responsible for about 90% of liver cancers. HCV is a virus that spreads rapidly and is becoming a problem on a global scale. Interferon alpha therapy is used to treat HCV infection to reduce cell growth and reproduction as well as to boost the immune system. An HCV patient's immune system normally produces trace levels of interferon-alpha in response to the hepatitis C virus. The establishment of an antiviral state is thereafter triggered by interferon adhesion, which binds to the receptor sites in the target cells and starts the transcription of 20–30 genes. Additionally, interferon is artificially provided to treat HCV disease and eradicate the biological effects of the virus on the side that is affected. The use of interferon or Peg- IFN plus ribavirin therapy is also linked to negative health outcomes. Methods: Of the 200 HCV Positive patients divided into three groups, which were enrolled in this study 100 (50%) were male, 100 (50%) were females, which total data of below 16 years of age were 27 (13.5%) in which 15 (7.5%) were males and 12 (12%) were females. According to 2nd age group, the total data of 17-25 age were 69 (34.5%) of which 33 (16.5%) were males and 36 (18%) were females. In 3rd age group, the total data of 26-34 age were 57 (28.5%) of which 28 (14%) were males and 29 (14.5%) were females. In the last 4th age group total data of 35 and above were 35 (17.5%) in which males were 24 (12%) and 23 (11.5%) were females. In the current study, both males and females of different age groups are included and followed at regular intervals. Changes in hematological parameters (blood CP and ALT) and other important information are recorded. Results: BELOW 16 YEARS AGE GROUP: 13.94% in the total leukocyte count (WBC) reduced in both sexes while in males 13.78% and 13.98 % in females. 10.7% in the red blood cells (RBC) reduced in both sexes while in males 10.5 % and 10.8 % in females. 29.96% in the platelet (Plt) count was reduced in both sexes while in 29.44 % in males and 30.13 % in females. 8.2% in the hemoglobin levels (HB) reduced in both sexes while in males 8.3% in males and 8.1 % in females. 17-25 YEARS AGE GROUP: 14.77 % in the total leukocyte count (WBC) reduced in both sexes while in males 14.35% and 14.81 % in females. 11.56% in the red blood cells (RBC) reduced in both sexes while in males 11.68 % and 11.44 % in females. 28.7 % in the platelet (Plt) count reduced in both sexes while in males 29.1% and 28.5 % in females. 7.5% in the hemoglobin levels (HB) reduced in both sexes while in males 7.8% and 7.4 % in females. 35 & Above AGE GROUP: 13.75% in the total leukocyte count (WBC) reduced in both sexes while in males 13.78% and 13.98 % in females. 13.13 % in the red blood cells (RBC) reduced in both sexes while in males 12.96 % and 13.27 % in females. 32.17% in the platelet (Plt) count reduced in both sexes while in males 32.31% and 32.05 % in females. 9.05 % in the hemoglobin levels (HB) reduced in both sexes while in males 8.82% and 9.19 % in females. Conclusions: In order to prevent severe side effects that could cause morbidity and mortality, rigorous hematological monitoring of blood CP and ALT levels at regular intervals is required. Biological sciences/Biotechnology Biological sciences/Microbiology Full Text Additional Declarations No competing interests reported. Supplementary Files before...xlsx completedata.xlsx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5717094","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":400138743,"identity":"eddb66fb-0dfb-4fd2-87ae-9a57deb9c792","order_by":0,"name":"Aziz Ur Rehman","email":"","orcid":"","institution":"Bacha khan University Charsadda Pakistan","correspondingAuthor":false,"prefix":"","firstName":"Aziz","middleName":"Ur","lastName":"Rehman","suffix":""},{"id":400138744,"identity":"83d607e4-e38f-4088-bb5d-c2795c1d1728","order_by":1,"name":"Sajjad Ali Shah","email":"","orcid":"","institution":"Bacha khan University Charsadda Pakistan","correspondingAuthor":false,"prefix":"","firstName":"Sajjad","middleName":"Ali","lastName":"Shah","suffix":""},{"id":400138745,"identity":"acd6a7fc-36b7-488a-9925-8c5a1489dcd3","order_by":2,"name":"Rehana Masood","email":"","orcid":"","institution":"Shaheed Benazir Bhutto Women University","correspondingAuthor":false,"prefix":"","firstName":"Rehana","middleName":"","lastName":"Masood","suffix":""},{"id":400138746,"identity":"44c80867-0113-4274-8f57-83912165c496","order_by":3,"name":"Aisha Siddique","email":"","orcid":"","institution":"women university mardan","correspondingAuthor":false,"prefix":"","firstName":"Aisha","middleName":"","lastName":"Siddique","suffix":""},{"id":400138747,"identity":"e0b4a213-a071-4978-aeb6-91d9b9b22bc0","order_by":4,"name":"Amir Atlas","email":"","orcid":"","institution":"Institute of Basic Medical Sciences, KMU","correspondingAuthor":false,"prefix":"","firstName":"Amir","middleName":"","lastName":"Atlas","suffix":""},{"id":400138748,"identity":"bbb65f82-a540-4f42-a529-bf55ba3fe0dd","order_by":5,"name":"Fayez althobaiti","email":"","orcid":"","institution":"Taif University","correspondingAuthor":false,"prefix":"","firstName":"Fayez","middleName":"","lastName":"althobaiti","suffix":""},{"id":400138749,"identity":"50f52a5d-57f2-4f10-b957-563a0a06cbc0","order_by":6,"name":"Fuad A. Awwad","email":"","orcid":"","institution":"King Saud University","correspondingAuthor":false,"prefix":"","firstName":"Fuad","middleName":"A.","lastName":"Awwad","suffix":""},{"id":400138750,"identity":"04245ca9-0302-4a9b-aa51-2cffecd80d0d","order_by":7,"name":"Emad A. A. Ismail","email":"","orcid":"","institution":"King Saud University","correspondingAuthor":false,"prefix":"","firstName":"Emad","middleName":"A. A.","lastName":"Ismail","suffix":""},{"id":400138751,"identity":"67251b20-83e6-4d40-8af6-9a1362999e83","order_by":8,"name":"Devendro Pratap Rao","email":"","orcid":"","institution":"Coordination Chemistry Laboratory, Dayanand Anglo-Vedic (PG) College","correspondingAuthor":false,"prefix":"","firstName":"Devendro","middleName":"Pratap","lastName":"Rao","suffix":""},{"id":400138752,"identity":"950daa68-8fb3-4815-82b1-9b89a354aa34","order_by":9,"name":"imad gul","email":"","orcid":"","institution":"Government post graduate college","correspondingAuthor":false,"prefix":"","firstName":"imad","middleName":"","lastName":"gul","suffix":""},{"id":400138753,"identity":"8839c688-1aa7-447f-88a4-4b61ca73f45a","order_by":10,"name":"Abdul Manan","email":"","orcid":"","institution":"Sichuan Agricultural University","correspondingAuthor":false,"prefix":"","firstName":"Abdul","middleName":"","lastName":"Manan","suffix":""},{"id":400138754,"identity":"f1d2677c-ef41-4e27-b452-e664710d6b4f","order_by":11,"name":"Fawad ALI","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA2UlEQVRIiWNgGAWjYBAC9gYgwQPEbGCWgQVhLTwHYFrALAMJErQwSCSASSK0sJ8x/PCm5o49n+Tzqxt+FEgw8Ld3J+DXwpNjLDnn2LPENumcsps9QIdJnDm7Aa8We4bcDdI8bIcT2KRz0m7wALUYSOTi18LD/3bzb55/h+3ZJM+k3fxDlBaJ3G3SvG2HGdsk2I/dJs4WifffLOf2HU5s48lhuy1jIMFD0C88/GnJN958O2wv33782c03f2zk+Nt78WtB1m0AJolVDgLsD0hRPQpGwSgYBSMIAABOikTS+x/p+AAAAABJRU5ErkJggg==","orcid":"","institution":"Bacha khan University Charsadda Pakistan","correspondingAuthor":true,"prefix":"","firstName":"Fawad","middleName":"","lastName":"ALI","suffix":""},{"id":400138755,"identity":"192dd3c5-0098-405b-8fca-f43345ae028e","order_by":12,"name":"Hamid Khan","email":"","orcid":"","institution":"International Islamic University, Islamabad","correspondingAuthor":false,"prefix":"","firstName":"Hamid","middleName":"","lastName":"Khan","suffix":""},{"id":400138756,"identity":"6a22d651-b8b4-42e4-94c6-1fea7399b9c4","order_by":13,"name":"Bahrul Amin","email":"","orcid":"","institution":"International Islamic University, Islamabad","correspondingAuthor":false,"prefix":"","firstName":"Bahrul","middleName":"","lastName":"Amin","suffix":""}],"badges":[],"createdAt":"2024-12-26 15:38:16","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-5717094/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5717094/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":83498801,"identity":"cf26eaa6-7eb6-469a-9705-5073c2fb24e4","added_by":"auto","created_at":"2025-05-27 12:38:59","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1130394,"visible":true,"origin":"","legend":"","description":"","filename":"azizpaperfinal1.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5717094/v1_covered_bb2f93a0-54b8-4c31-a506-6b1f5d25f54b.pdf"},{"id":73698968,"identity":"075d896c-80b4-4014-87f9-313a07938d72","added_by":"auto","created_at":"2025-01-13 16:48:37","extension":"xlsx","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":39914,"visible":true,"origin":"","legend":"","description":"","filename":"before...xlsx","url":"https://assets-eu.researchsquare.com/files/rs-5717094/v1/d60589da44480b3621ca93d4.xlsx"},{"id":73697465,"identity":"1034891c-fa0d-4388-90fd-eefdec980a8d","added_by":"auto","created_at":"2025-01-13 16:32:37","extension":"xlsx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":39914,"visible":true,"origin":"","legend":"","description":"","filename":"completedata.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-5717094/v1/52fdaa3438fe7e008b88803a.xlsx"}],"financialInterests":"No competing interests reported.","formattedTitle":"\u003cp\u003eEffect of Pegylated-interferon (Peg-inf) Plus Ribavirin (Rbv) Therapy on Haematological Profile of Different Age Groups Infected by Hepatitis C Virus in Pakistan\u003c/p\u003e","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-5717094/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5717094/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eBackground and Aims: With an estimated 11.55% adult population carrying HCV, hepatitis is a serious public health concern in Pakistan. With almost one in every 20 Pakistanis already infected, the nation ranks second internationally in terms of hepatitis C virus (HCV) infections. HBV and HCV each have annual mortality rates of 563,000 and 366,000, respectively. Hepatocellular carcinoma (HCC) is the most common primary liver tumor responsible for about 90% of liver cancers. HCV is a virus that spreads rapidly and is becoming a problem on a global scale. Interferon alpha therapy is used to treat HCV infection to reduce cell growth and reproduction as well as to boost the immune system. An HCV patient's immune system normally produces trace levels of interferon-alpha in response to the hepatitis C virus. The establishment of an antiviral state is thereafter triggered by interferon adhesion, which binds to the receptor sites in the target cells and starts the transcription of 20–30 genes. Additionally, interferon is artificially provided to treat HCV disease and eradicate the biological effects of the virus on the side that is affected. The use of interferon or Peg- IFN plus ribavirin therapy is also linked to negative health outcomes.\u003c/p\u003e\n\u003cp\u003eMethods: Of the 200 HCV Positive patients divided into three groups, which were enrolled in this study 100 (50%) were male, 100 (50%) were females, which total data of below 16 years of age were 27 (13.5%) in which 15 (7.5%) were males and 12 (12%) were females. According to 2nd age group, the total data of 17-25 age were 69 (34.5%) of which 33 (16.5%) were males and 36 (18%) were females. In 3rd age group, the total data of 26-34 age were 57 (28.5%) of which 28 (14%) were males and 29 (14.5%) were females. In the last 4th age group total data of 35 and above were 35 (17.5%) in which males were 24 (12%) and 23 (11.5%) were females. In the current study, both males and females of different age groups are included and followed at regular intervals. Changes in hematological parameters (blood CP and ALT) and other important information are recorded.\u003c/p\u003e\n\u003cp\u003eResults: BELOW 16 YEARS AGE GROUP: 13.94% in the total leukocyte count (WBC) reduced in both sexes while in males 13.78% and 13.98 % in females. 10.7% in the red blood cells (RBC) reduced in both sexes while in males 10.5 % and 10.8 % in females. 29.96% in the platelet (Plt) count was reduced in both sexes while in 29.44 % in males and 30.13 % in females. 8.2% in the hemoglobin levels (HB) reduced in both sexes while in males 8.3% in males and 8.1 % in females. 17-25 YEARS AGE GROUP: 14.77 % in the total leukocyte count (WBC) reduced in both sexes while in males 14.35% and 14.81\u003c/p\u003e\n\u003cp\u003e% in females. 11.56% in the red blood cells (RBC) reduced in both sexes while in males\u003c/p\u003e\n\u003cp\u003e11.68 % and 11.44 % in females. 28.7 % in the platelet (Plt) count reduced in both sexes while in males 29.1% and 28.5 % in females. 7.5% in the hemoglobin levels (HB) reduced in both sexes while in males 7.8% and 7.4 % in females. 35 \u0026amp; Above AGE GROUP: 13.75% in the total leukocyte count (WBC) reduced in both sexes while in males 13.78% and 13.98 % in females. 13.13 % in the red blood cells (RBC) reduced in both sexes while in males 12.96 % and 13.27 % in females. 32.17% in the platelet (Plt) count reduced in both sexes while in males 32.31% and 32.05 % in females. 9.05 % in the hemoglobin levels (HB) reduced in both sexes while in males 8.82% and 9.19 % in females.\u003c/p\u003e\n\u003cp\u003eConclusions: In order to prevent severe side effects that could cause morbidity and mortality, rigorous hematological monitoring of blood CP and ALT levels at regular intervals is required.\u003c/p\u003e","manuscriptTitle":"Effect of Pegylated-interferon (Peg-inf) Plus Ribavirin (Rbv) Therapy on Haematological Profile of Different Age Groups Infected by Hepatitis C Virus in Pakistan","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-01-13 16:32:32","doi":"10.21203/rs.3.rs-5717094/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"2c9c815e-52bb-4ce2-82d4-2d848a1582ae","owner":[],"postedDate":"January 13th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":42800500,"name":"Biological sciences/Biotechnology"},{"id":42800501,"name":"Biological sciences/Microbiology"}],"tags":[],"updatedAt":"2025-05-27T12:38:22+00:00","versionOfRecord":[],"versionCreatedAt":"2025-01-13 16:32:32","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-5717094","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5717094","identity":"rs-5717094","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}